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Abstract
Large numbers of observational studies have described a decrease in the incidence of
cardiovascular disease in women taking hormone replacement therapy (HRT). The potential
mechanisms for this effect are numerous, including direct effects on lipid levels and lipid
metabolism, cardiovascular dynamics, and endothelial reactivity. The beneficial effects of
HRT are probably affected by various factors, including the age of onset of therapy, the
presence of coronary artery disease, the type of estrogen and whether it is used in
combination with progesterone, concurrent modification of other cardiac risk factors, and
duration of therapy. Until further prospective clinical trials are done, HRT should be
considered in those women for whom the potential benefits exceed the potential risks, on
the basis of an individualized patient evaluation.
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Introduction
At the end of the 20th century, coronary heart disease
(CHD) remains the most common cause of death among
both men and women in most of the westernized world.
The increased relative risk for CHD death in men (2.5- to
4.5-fold) compared with women is seen in countries with
high or low rates of heart disease [1]. This male surplus
of CHD in diverse populations with very divergent
lifestyles, eating patterns, and disease rates is only com-
patible with an intrinsic female advantage or a male disad-
vantage [2]. The female advantage has naturally been
attributed to estrogen.
There are many reasons to believe that estrogen is cardio-
protective. The fact that CHD is uncommon in women
before 50 years of age (average age of menopause
49–51 years), that postmenopausal women demonstrate
increased rates of CHD compared to premenopausal
women of the same age range, and the increased risk of
CHD after premature menopause lend support to the
estrogen–CHD hypothesis [3]. Numerous in vivo and in
vitro studies show at least a dozen estrogen effects that
would be expected to prevent or delay CHD [4]. Observa-
tional studies have almost universally reported a lower risk
of CHD in postmenopausal women who take estrogenCurrent Controlled Trials in Cardiovascular Medicine    Vol 1 No 3 Johnson and Sweeney
alone or with a progestin as compared with those women
who do not [1–3,5]. This trend has also been demon-
strated in women with established CHD [6].
Menopause
On average, women develop heart disease approximately
10 years later than men, but the largest increase in coro-
nary mortality coincides with the menopause [7]. Estradiol
levels in postmenopausal women are reduced by approxi-
mately 75% compared with premenopausal levels. The
degree to which estrogen deficiency contributes to CHD
risk in women has not been definitively established, and
cross-sectional and prospective studies have generally
failed to find an association between endogenous estro-
gen levels and CHD risk factors in women or men [8].
Data from vital statistics also do not support a conclusion
that menopause, apart from the effects of chronological
aging, increases the risk for CHD. Obviously, these
studies cannot completely exclude a cardioprotective
effect of endogenous estrogen since a single hormone
assay may be inadequate to correctly classify individuals
with regard to their usual endocrine status. It seems likely
that both aging and estrogen decline contribute to
increased CHD risk [9].
Data from women who undergo premature menopause –
natural or surgical – indicate that CHD develops prema-
turely in these women, supporting the concept that
menopause and CHD are linked. Autopsy studies [10]
have shown a clear increase in coronary disease in
women after oophorectomy or premature ovarian failure.
There are many possible confounding variables in these
studies, including changes in hypothalmic and pituitary
hormone levels after surgery, and the antecedent
disease processes that necessitated oophorectomy or
caused the ovarian failure. More recent studies have
yielded inconsistent results [11]. In the Nurses’ Health
Study [5], bilateral oophorectomy, but not natural
menopause, was associated with an increased risk for
CHD. No increased risk was observed in oophorec-
tomized women who had been treated with estrogen.
The fact remains, however, that after oophorectomy the
incidence of CHD in women is increased.
Perhaps the most dramatic evidence suggesting that loss
of endogenous estrogen increases cardiac risk is the
sharp increase in low-density lipoprotein (LDL)-cholesterol
that begins during the perimenopausal period and contin-
ues to at least age 60 years, with these higher levels sus-
tained thereafter [12]. Interestingly, both cross-sectional
and prospective studies show only a small decrease in
high-density lipoprotein (HDL)-cholesterol levels at the
time of menopause; on average, HDL-cholesterol levels in
women remain higher than those in men for at least
another 30 years after menopause [8].
Hormone replacement therapy and risk factors
for coronary heart disease
A number of biologically plausible mechanisms exist for
hormone-mediated protection from CHD. The Post-
menopausal Estrogen/Progestin Intervention (PEPI) trial
[13] examined the effect of HRT [conjugated equine
estrogen alone or in various combinations with medrox-
yprogesterone acetate (MPA) or micronized proges-
terone] on cardiovascular risk factors. The PEPI trial and
numerous observational studies have shown that oral
estrogen therapy is associated with a 10–15% increase
in HDL-cholesterol and a similar decrease in LDL-cho-
lesterol. The elevation in HDL-cholesterol is due to
increased production of HDL2 and apolipoprotein A-1,
whereas the decrease in LDL-cholesterol is due to
increased expression of hepatic LDL receptors. All
progestins are not alike, however, and the PEPI trial
found differences in the effects of different HRT prepa-
rations on CHD risk factors. While all women who
received estrogen had an increase in HDL-cholesterol
and a decrease in LDL-cholesterol, the HDL-cholesterol
effect was more pronounced with micronized proges-
terone than with MPA. Progestins, such as MPA, have
been found to reduce the beneficial effects of estrogen
on endothelial function and on atherosclerosis in several
animal models [14]. The benefits and risks of cyclic
versus daily progestin regimens also have not been fully
determined.
Oxidation of LDL-cholesterol is believed to be an initiating
event in atherogenesis, and estradiol and/or other estro-
gens may inhibit this process [15]. Oral conjugated estro-
gens are also associated with increases in very
low-density lipoprotein, triglycerides, and apolipoprotein B
levels, as well as with decreases in lipoprotein(a) levels.
These are not large changes, however, and the effects of
modest alterations in these molecules on the development
of CHD are uncertain.
In addition, estrogen has multiple other effects expected
to be cardioprotective. These include favorable changes
in postprandial lipid metabolism, plasminogen activator
inhibitor-1, fibrinogen, antithrombin III, homocysteine
levels, carbohydrate metabolism, atheroma formation, car-
diovascular hemodynamics, and endothelial dysfunction
[4,16,17].
On the other hand, the PEPI investigators [18] found that
HRT rapidly increases the level of C-reactive protein (a
marker of inflammation that has been associated with
increased risk of cardiovascular events) while reducing
the levels of soluble E-selectin (a possible anti-inflamma-
tory effect). As pointed out by those investigators, such
data underscore the need to study the effect of
HRT-mediated changes in inflammation on the risk of
subsequent coronary events.http://cvm.controlled-trials.com/content/1/3/139
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Observational evidence and randomized trials
Since the 1970s, more than 30 case–control and
prospective studies have reported a decrease in risk for
CHD in women on HRT. In the most recent meta-analy-
sis, Barrett-Connor and Grady [1] estimated that estro-
gen therapy alone was associated with a 35–50%
reduction, and estrogen–progesterone with a 33%
reduction in the risk of coronary disease, as compared
with women who were not on HRT. These observational
data are extensive and largely consistent.
In the Lipid Research Clinic Follow-up Study [6], 2270
hyperlipidemic, Caucasian women aged 40–69 years at
study entry were followed for more than 8 years. Over
60% fewer CHD deaths occurred in women who received
estrogen than in those who did not. This benefit remained
after adjustment for age, hypertension, and smoking, and it
was most pronounced in women with known CHD.
It has been suggested that observational studies may
overestimate the amount of protection attributed to estro-
gen. Numerous biases in the epidemiologic studies have
been identified (compliance, healthy user, prescription,
prevention, survivor) [19]. Only randomized trials can
control for both known and unknown differences in
women who do and do not elect to take medication.
The only large, randomized clinical trial testing the benefit
of HRT – the Heart and Estrogen/Progestin Replacement
Study (HERS) [20] – found no overall benefit of HRT on
secondary prevention of CHD in 2763 postmenopausal
women with established coronary disease who were
treated for an average of 4.1 years (relative risk 0.99, 95%
confidence interval 0.80–1.22). HRT was associated with
more secondary cardiac events as compared to placebo
during year 1 of treatment, and with a significant trend
toward fewer events in years 4 and 5.
At face value the results of HERS are not consistent with
our knowledge of estrogen’s action on the cardiovascular
system and the many observational studies showing estro-
gen’s benefit, and it is premature and counterintuitive to
rely only on the results of this one study. This was an older
cohort of women (mean age 67 years) with significant
heart disease. More than 80% of the HERS study group
had revascularization within 6 months of study entry,
which could have resulted in the low event rates in both
the placebo and treatment arms (the event rate in the
placebo group was 50% lower than that in the treatment
group during the first year). The HERS selection criteria
also excluded women with uncontrolled diabetes or hyper-
tension, which also may have resulted in low event rates.
Most women in observational studies began using HRT
during the perimenopausal or early postmenopausal
period [2]. In the HERS study, women were an average of
18 years past the cessation of menses. Only 46% of
patients received cholesterol-lowering statins (3-hydroxy-
3-methylglutaryl coenzyme A reductase inhibitors) and diet
modification in addition to HRT, even though more than
90% had LDL-cholesterol in excess of 100mg/dl at base-
line. The majority of those taking statins did not achieve
target goals for lipid reduction. Statins have been shown
in clinical trials to reduce the risk of CHD in women with or
without known heart disease. Another significant variable
is if the choice of HRT used in the HERS (a fixed-combina-
tion estrogen and progestin) played a role in increasing
CHD events. Since a comparison group taking estrogen
alone was not included, and some progestins are thought
to attenuate the benefits of estrogen on the cardiovascular
system, the possibility exists that a different regimen may
have offered greater benefits.
Conclusion
Before HERS, the real controversy over hormone therapy
was whether all postmenopausal women were likely to
derive cardioprotective benefit and should therefore be
encouraged to use HRT. Despite the nearly universal find-
ings from observational studies that postmenopausal estro-
gen therapy reduces the risk of CHD and the multiple
mechanisms by which estrogen might be beneficial,
hormone therapy had no benefit in the only large random-
ized clinical trial to date. At this time, what we have really
learned from HERS is that, in older women with severe
CHD, a fixed estrogen–progestin regimen should not be
prescribed with the expectation that it will decrease the
incidence of cardiovascular events in the short term.
Women who are already on HRT should probably continue
with the regimen because there appears to be a protective
effect of HRT on the cardiovascular system after the first
few years of use. On the basis of the results of the HERS
trial, a consensus panel of the American Heart Association
and the American College of Cardiology [21] has sug-
gested that initiation or continuation of HRT should be con-
sidered in those women for whom the potential benefits of
therapy may exceed the potential risks based on individual-
ized patient history. Thus, although there is significant evi-
dence that HRT is protective in postmenopausal women in
the primary prevention of CHD, further large-scale studies
of HRT in women with established CHD are warranted,
especially with other HRT regimens.
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